Hepatic Medicine Evidence Research Open Access Full Text Article Dovepress open access scientific medical research REv iEw The pathophysiology thrombocytopenia chronic liver disease Oscar Mitchell1 David M Feldman12 Marla Diakow1 Samuel H Sigal3 1Department Medicine 2Division Gastroenterology Liver Diseases New York University School Medicine Langone Medical Center New York 3Division Gastroenterology Liver Diseases Department Medicine Montefiore Medical Center Albert Einstein College Medicine Bronx NY USA Correspondence Samuel H Sigal Division Gastroenterology Liver Diseases Department Medicine Montefiore Medical Center Albert Einstein College Medicine 111 East 210th Street Bronx NY 10467 USA Tel 1 718 920 6240 Fax 1 718 547 4773 Email ssigalmontefioreorg Abstract Thrombocytopenia common hematological abnormality encountered patients chronic liver disease CLD In addition indicator advanced disease poor prognosis frequently prevents crucial interventions Historically thrombocytopenia attributed hypersplenism increased pooling platelets spleen enlarged congestive splenomegaly secondary portal hypertension Over past decade significant advances understanding thrombopoiesis turn led improved understanding thrombocytopenia cirrhosis Multiple factors contribute development thrombocytopenia broadly divided cause decreased production splenic sequestration increased destruction Depressed thrombopoietin levels CLD direct bone marrow suppression result reduced rate platelet production Thrombopoietin regulates platelet production maturation impaired CLD Bone marrow suppression caused viruses alcohol iron overload medications Splenic sequestration results hypersplenism The increased rate platelet destruction cirrhosis occurs number pathways increased shear stress increased fibrinolysis bacterial translocation infection result increased rate platelet aggregation autoimmune disease raised titers antiplatelet immunoglobulin result immunologic destruction platelets An indepth understanding complex pathophysiology thrombocytopenia CLD crucial considering treatment strat egies This review outlines recent advances understanding thrombocytopenia cirrhosis CLD Keywords cirrhosis thrombocytopenia thrombopoietin Introduction Thrombocytopenia common hematological abnormality encountered patients chronic liver disease CLD1 occurring 6484 patients cirrhosis fibrosis2 Among patients undergoing bone marrow biopsies thrombocy topenia unknown etiology prevalence cirrhosis high 353 In addition indicator advanced disease4 thrombocytopenia associated poorer prognosis1 frequently prevents patients receiving crucial interventions medications invasive diagnostic therapeutic procedures5 Historically thrombocytopenia attributed hypersplenism increased pooling platelets spleen enlarged congestive splenomegaly secondary portal hypertension6 Over past decade significant advances understanding thrombopoiesis turn led improved understanding thrombocytopenia cirrhosis Multiple factors submit manuscript wwwdovepresscom Dovepress httpdxdoiorg102147HMERS74612 Hepatic Medicine Evidence Research 20168 3950 39 2016 Mitchell et al This work published licensed Dove Medical Press Limited The terms license available httpswwwdovepresscomterms php incorporate Creative Commons Attribution Non Commercial unported v30 License httpcreativecommonsorglicensesbync30 By accessing work accept Terms Noncommercial uses work permitted permission Dove Medical Press Limited provided work properly attributed For permission commercial use work paragraphs 42 5 Terms httpswwwdovepresscomtermsphp Mitchell et al Dovepress contribute development thrombocytopenia cirrhotic patient broadly divided leading decreased production splenic sequestration increased destruction Figure 1 This review outlines recent advances understanding pathophysiology thrombocytopenia cirrhosis Decreased platelet production Platelet production decreased depressed thrombopoietin TPO levels direct bone marrow suppression Thrombopoietin Hepatic production TPO plays pivotal role throm bopoiesis Figure 2 In 1990 oncogene vmpl identified murine myeloproliferative leukemia virus capable immortalizing bone marrow hematopoietic cells different lineages7 In 1992 human homologue cmpl cloned sequence data revealed encoded protein homologous members hematopoietic receptor superfamily8 Antisense oligodeoxynucleotides cmpl shown selectively inhibit megakaryocyte colony formation dem onstrating cmpl regulated thrombopoiesis9 The ligand cmpl TPO cloned 1994 It 353amino acid transmembrane domain extra cellular cytokine receptor domains intracellular cytokine receptor box motifs10 TPO major regulator megakaryocytopoiesis regulates platelet pro duction maturation It glycoprotein GP shares significant amino acid sequence homology erythro poietin EPO11 TPO primarily liver parenchymal cells sinusoidal endothelial cells secreted circulation constant rate12 After binding surface platelets megakaryo cytes cmpl receptor13 TPO internalized destroyed reducing platelet megakaryo cyte exposure hormone14 Stimulation TPO receptor results activation number signaling path ways Janus kinase type 2 JAK2 tyrosine kinase 2 TYK215 Mitogenactivated protein kinase activation sub sequently leads changes gene expression promoting progression stem cells megakaryocytic pathway megakaryocyte maturation subsequent release mally functioning platelets peripheral circulation16 Because circulating level TPO inversely correlated platelet mass low platelet counts lead higher TPO levels decreased degradation Figure 3 The increased exposure undifferentiated bone marrow cells TPO leads differentiation megakaryocytes maturation This increased platelet cell mass turn binds increasing amounts TPO reducing circulation level leading decreased platelet production This negative feedback mechanism highlighted observation mice genetically altered defective cmpl low platelet megakaryocyte numbers elevated TPO levels17 Decreased hepatic production TPO critical fac tor development thrombocytopenia cirrhosis Figure 4 The prevalence severity thrombocytopenia correlate parallel severity underlying liver disease particularly extent fibrosis18 The prevalence thrombocytopenia higher patients Stages 3 4 fibrosis compared patients Stages 02 fibrosis 64 vs 62 There inverse relationship TPO levels liver function assessed tests measure liver function indocyanine green retention aminopyrine breath tests19 Cirrhotic patients thrombo cytopenia lower levels circulating TPO Thrombocytopenia liver disease Reduced production Sequestration Increased destruction Reduced TPO Reduced bone marrow production Shear stress Immunologic destruction Hyperfibrinolysis Bacterial translocation Sepsis Viruses Alcohol Iron Medication ITP HCV DITP Sepsis Figure 1 Factors contribute development thrombocytopenia patients cirrhosis Note The factors categorized result decreased production splenic sequestration increased destruction Abbreviations DiTP druginduced thrombocytopenia HCv hepatitis C virus iTP idiopathic thrombocytopenia purpura TPO thrombopoietin 40 submit manuscript wwwdovepresscom Dovepress Hepatic Medicine Evidence Research 20168 Dovepress Thrombocytopenia chronic liver disease Normal thrombopoiesis TPO production TPO Binding cmpl receptor megakaryocyte platelets Megakaryocytes Platelets Internalization Platelet production TPO degradation TPO degradation Figure 2 Normal thrombopoiesis Notes The liver secretes TPO constant rate circulation binds cmpl ligands platelets megakaryocytes TPO bound platelets internalized degraded TPO bound megakaryocytes stimulates platelet production Abbreviation TPO thrombopoietin normal platelet counts20 The key role played TPO thrombocytopenia CLD highlighted interaction TPO platelets perioperative period liver transplantation TPO levels undetectable patients cirrhosis transplantation rise immediately posttransplantation followed rise peripheral platelet count normalization TPO levels platelet count patients 14 days21 Bone marrow suppression Inadequate production platelets bone marrow sup pression selected cases play crucial role development thrombocytopenia cirrhosis22 Possible etiologies include suppression viruses alcohol iron load medications viruses Hepatitis A virus hepatitis B virus hepatitis C virus HCV directly inhibit growth differen tiation human bone marrow progenitor cells vitro23 Thrombocytopenia especially common patients infected HCV variety mechanisms direct bone marrow suppression24 Patients HCV splenomegaly depressed platelet production25 production increases successful treatment infection26 Alcohol Thrombocytopenia occurs frequently alcoholics direct effect bone marrow27 Alcohol reduces plate let life span leads ineffective megakaryopoiesis27 Hepatic Medicine Evidence Research 20168 submit manuscript wwwdovepresscom Dovepress 41 Mitchell et al Dovepress Thrombocytopenia TPO production Secretion TPO Decreased platelet binding Megakaryocytes Thrombocytopenia decreased cmpl binding Increased platelet production Decreased internalization Decreased TPO degradation Increased TPO levels Figure 3 increased thrombopoietin levels thrombocytopenia lead increased platelet production Note states thrombocytopenia absence chronic liver disease decreased TPO binding degradation circulating platelets leading higher levels available increased megakaryocyte stimulation platelet production Abbreviation TPO thrombopoietin Following alcohol withdrawal platelet counts rise 57 days normalize weeks28 iron The status iron stores important factor throm bopoiesis especially determining response EPO Thrombocytosis common presentation iron defi ciency anemia29 suggested serves protective mechanism increasing coagulation capacity conditions chronic bleeding30 Repletion iron deficiency renal failure inflammatory bowel disease contrast leads decrease platelet levels occasionally precipitous reductions develop ment thrombocytopenia31 Experimental studies indicate thrombocytosis iron deficiency increased commitment hematopoietic progenitors mega karyocytic lineage accelerated differentiation independent EPO TPO30 The elevated EPO levels normal physiological response anemia32 affect platelet production biphasic response An early transient increase platelet count followed development thrombocytopenia 42 submit manuscript wwwdovepresscom Dovepress Hepatic Medicine Evidence Research 20168 Dovepress Thrombocytopenia chronic liver disease Cirrhosis Reduced TPO ReReReReReReReReReReReReReReReReRedududududududududududddduddudducecececcecceecececececeeedddddddddddddddd TPTPTPTPTPTPTTPTPTTPTPPTPPOOOOOOOOOO production prprprprprprprprprprppppp odododododododododdodododoo ucuucucucucucuucuccucucuuu titititiitititiionononononononooooo Reduced d n secretion Decreased TPO levels Splenomegaly Splenic sequestration Decreased cmpl binding Increased TPO binding d internalization degradation Megakaryocytes Reduced platelet production Thrombocytopenia Figure 4 Decreased thrombopoietin levels cirrhosis lead decreased platelet production Notes patients chronic liver disease circulating TPO levels decreased impaired production secretion increased internalization degradation platelets sequestered enlarged spleen Reduced TPO levels result decreased megakaryocyte stimulation platelet production Adapted permission Pacific Health Wellness124 Reproduced permission Cognition Studio inc125 Abbreviation TPO thrombopoietin observed EPO treatment functional iron deficiency33 The liver serves central role iron storage func tions main site synthesis iron transport proteins Hepcidin principal iron regulatory hormone produced hepatocytes34 secreted circulation binds ferroportin macrophages enterocytes inducing internalization degradation ferroportin inhibiting iron export35 Excess iron inflammation triggers increased hepcidin expression36 resulting decreased enterocyte iron absorption reduced iron release macrophages Increased hepcidin expression implicated anemia inflammation37 decreased hepcidin expression plays important role hemochromatosis38 Iron overload associated spur cell hemolytic ane mia common advanced cirrhosis occurring mechanisms39 Prohepcidin expression reduced proportion severity liver disease40 leading decreased hepcidin levels increased iron absorption Spur cell hemolytic anemia caused combination altered red blood cell RBC membrane composition oxida tive damage decreased RBC membrane fluidity leads decreased RBC survival hemolytic anemia41 contributes increased iron absorption hepatic iron loading42 Experimentally iron status major determi nant platelet response EPO Compared animals depletion iron stores animals iron overload ing pronounced degree thrombocytopenia Hepatic Medicine Evidence Research 20168 submit manuscript wwwdovepresscom Dovepress 43 Mitchell et al Dovepress competition erythroid megakaryocytic development pathways stem cells absence protection afforded iron deficiency33 Medications Cirrhotic patients exposed plethora drugs potential cause druginduced thrombocytopenia DITP multiple mechanisms include direct bone marrow suppression immunological platelet destruction Examples medications commonly prescribed cirrhotic patient associated impaired thrombopoiesis include azathioprine antibiotics interferon IFN Azathioprine purine antimetabolite immu nosuppressive agent treat range autoimmune disorders including chronic autoimmune hepatitis Its mechanism action blocking purine synthesis hinders proliferation cell lines pronounced effect lymphocytes The common effect agent bone marrow suppression effect dose dependent Although 5 patients taking azathioprine bone marrow toxicity include thrombo cytopenia 243 effective therapy frequently possible cirrhotic patients baseline thrombocytopenia Betalactam antibiotics fluoroquinolones proposed potential causes thrombocytopenia acting bone marrow suppression44 IFNbased therapies recently standard care patients chronic hepatitis C Because dose dependent thrombocytopenia frequent effect IFN baseline thrombocytopenia cirrhotic patients frequently prevented receiving effective therapy IFNinduced bone marrow toxicity resultant cytopenias com mon reason treatment discontinuation cessation45 The mechanism development IFNinduced thrombocy topenia multifactorial includes direct impairment latestage megakaryocytopoiesis46 altered TPO levels IFN inhibits expression transcription factors regulating latestage megakaryocytopoiesis impairs thrombopoiesis preventing cytoplasmic maturation megakaryocytes preventing platelet production46 It associated blunted TPO response thrombocytopenia direct reduction TPO levels47 Patients advanced liver disease especially lack appropriate compensatory increase TPO response thrombocytopenia47 Splenic sequestration Historically thrombocytopenia cirrhosis attributed increased pooling platelets enlarged spleen6 The term hypersplenism 1909 presence splenomegaly patients hemolytic anemia The concept subsequently evolved distinct clinical syndrome splenic hyperactivity associated splenomegaly reduction peripheral cell types appropriately proliferative bone marrow response potential reversal splenectomy48 Congestive splenomegaly develops result portal hypertension characterized redistribution blood flow platelets circulating pool splenic pool49 As result splenomegaly leads thrombocytopenia seques tration inverse relationship spleen size platelet count18 Because sequestrated platelets capable removing TPO circulation contribute development thrombocytopenia lowering TPO levels50 Increased platelet destruction Increased platelet destruction occurs cirrhosis increased shear stress leading increased rate platelet aggregation immunologic destruction increased fibrinolysis bacterial translocation infection Shear stress Shear stress level fluid stress applied platelets plasma components vasculature provokes platelet aggregation Under conditions excessive high fluid shear stress ultralarge von Willebrand factor ULVWF undergoes conformational transition globular state extended chain conformation adhesive platelets5152 This leads aggregated complexes vasculature thrombus formation ADAMTS13 disintegrinlike metalloprotease thrombospondin type 1 motif 13 sheardependent metalloproteinase produced hepatic stellate cells cleaves unusually large vWF5354 High levels shear stress enhance vWFplatelet aggregation promote cleavage vWF ADAMTS1355 The levels activity ADAMTS13 reduced patients advanced cirrhosis56 enhanced consump tion ADAMTS13 presence inflammatory cytokines presence ADAMTS13 plasma inhibitor57 Decreased levels ADAMTS13 result accumulation ULVWFM turn enhances high shearstress induced platelet aggregation Low platelet counts cirrhosis paralleldepressed levels ADAMTS13 activity56 Finally TPO prime platelet aggregation conditions high shear stress portal hypertension congestive splenomegaly58 44 submit manuscript wwwdovepresscom Dovepress Hepatic Medicine Evidence Research 20168 Dovepress Thrombocytopenia chronic liver disease immunologic destruction Immunemediated destruction involving antiplatelet antibod ies frequently present cirrhosis Among patients CLD diverse etiologies 64 plateletassociated antiGP antibodies primarily directed GP IIbIX complex59 Lower platelet counts patients cirrhosis correlated larger spleen volumes higher levels plateletassociated immunoglobulin G PAIgG60 In study utilizing kinetic radiolabeled platelet techniques platelet levels directly correlated platelet survival times inversely correlated PAIgG levels splenic volumes61 Specific situations immunemediated thrombocytopenia encountered include idiopathic thrombocytopenia purpura ITP chronic hepatitis C infection medications idiopathic thrombocytopenia purpura ITP known immune autoimmune thrombocy topenia purpura autoimmune disease characterized thrombocytopenia caused interaction PAIg platelet antigens62 In classic ITP autoantibodies pre dominantly exclusively produced platelet GP IIbIIIa IbIX63 Antibodycoated platelets recog nized macrophages spleen liver removed circulation64 Splenomegaly typically present patients usually respond immunosuppression65 Autoimmune liver diseases autoimmune hepatitis primary biliary cirrhosis PBC frequently associated autoimmune conditions Approximately 50 patients PBC affected additional autoimmune disease include ITP66 Up 40 patients PBC raised levels PAIgG66 case reports patients autoimmunerelated liver disease ITP67 Viral infections associated ITP especially HCV Up 30 patients ITP evidence advanced liver disease seropositive HCV68 The rate ITP patients infected HCV 302 100000 personyears compared 185 100000 person years nonHCVinfected individuals69 HCVrelated ITP thrombocytopenia severe usually affecting women usually good response corticosteroids70 Finally ITP described association viral infections including cytomegalovirus EpsteinBarr Virus71 Chronic hepatitis C Chronic infection HCV lead thrombocytopenia multiple mechanisms summarized Weksler72 Chronic HCV infection associated plethora autoimmune disorders Approximately 38 patients HCV infection exhibit immunemediated extra hepatic manifestation course disease73 Patients CLD HCV develop thrombocytopenia parallels severity disease mirrored increasing titers PAIg2574 HCV interact directly platelets bind platelet membranes multiple cell surface receptors75 AntiHCV antibodies coat surfaceassociated HCV ultimately leading phagocytosis antibodycoated platelets accelerated platelet destruc tion reticuloendothelial system75 The binding HCV platelets induce neoantigens platelet surface drive alterations platelet membrane GPs contributing autoantibody formation platelet mem brane GPs GPIIbIIIa subsequent development ITP76 Finally HCV intimately related cryoglobuline mia cryoglobulins play role immune complex formation accelerated platelet clearance70 immunemediated druginduced thrombocytopenia Due multiple medications cirrhotic patients receive DITP commonly encountered In DITP drug dependent antibodies bind specific platelet GPs pres ence offending drug Platelet counts decrease 57 days exposure causative agent rise 10 days cessation77 Causes DITP include antibiotics cephalosporins linezolid octreotide2024 The hall mark immunerelated DITP severe thrombocytopenia platelet count 30109L accompanied petechiae mucocutaneous bleeding78 IFN therapy rarely induce autoimmune ITP IFN induced autoimmune ITP reported develop 4 weeks 12 months therapy79 completion therapy80 In contrast dosedependent thrombocytopenia caused IFNinduced bone marrow suppression IFNinduced autoimmune ITP cause pre cipitous decreases platelet levels usually responds immunosuppression79 Heparininduced thrombocytopenia HIT commonly encountered causes DITP Following exposure heparin platelet factor 4 PF4 forms com plexes negatively charged heparin molecules81 These complexes highly immunogenic result formation HIT antibodies subsequent aggregation platelets PF4heparin complexes82 HIT common patients treated unfractionated heparin occurs frequency 36 7 days83 In contrast Hepatic Medicine Evidence Research 20168 submit manuscript wwwdovepresscom Dovepress 45 Mitchell et al Dovepress aforementioned classic druginduced immune thrombocy topenia HIT characterized usually moderate degree thrombocytopenia median platelet count nadir 50109L high risk venous andor arterial thrombosis bleeding84 Increased fibrinolysis The liver plays pivotal role fibrinolytic responsible sustaining balance bleeding thrombosis maintain homeostasis The liver important production multiple factors involved process clearance breakdown products Under mal circumstances deposition fibrin vascular triggers conversion plasminogen active enzyme plasmin degrades fibrin liberates fibrin fibrinogen degradation products circulation85 This plasminogentoplasmin conver sion driven tissue plasminogen activator tPA opposed plasminogen activator inhibitor PAI86 Alpha 2antiplasmin major inhibitors plasmin fibrinolysis87 Thrombinactivatable fibrinolysis inhibitor TAFI inhibits recruitment plasminogen thrombi slowing fibrinolysis88 Fibrinolysis increased cirrhosis There reduced production clotting inhibitory factors decreased clearance activated factors leading acceler ated intravascular coagulation There decreased clear ance tPA PAI1 circulation89 decreased hepatic synthesis alpha2antiplasmin TAFI90 As result rebalanced state pro antifi brinolytic factors leads hyperfibrinolysis 3046 patients endstage liver disease91 This hypercoagulable state excessive platelet consump tion plays role development thrombocytopenia cirrhosis supported studies platelet kinetics analysis92 A retrospective autopsy study patients liver disease platelet counts patients thrombotic complications lower thrombosis suggesting increased thrombosis consumes platelets93 Antifibrinolytic agents tranexamic acid aprotinin epsilonaminocaproic acid shown reduce intraoperative bleeding liver transplantation cirrhotic patients bleeding associated hyperfibrinolysis9497 Bacterial translocation Bacterial translocation associated endotoxemia com mon cirrhosis accelerate platelet consumption development thrombocytopenia High levels circulating endotoxins observed cirrhosis clinically infected98 Kalambokis Tsianos99 postulated role endotoxin pathophysiology thrombocytopenia cirrhosis intestinal bacterial growth altered gut permeability allow bacterial translo cation microorganisms intestinal lumen portal circulation100 Impairment reticuloendothelial system101 portosystemic shunting accounts presence systemic circulation102 Endotoxin accelerates release proinflammatory cytokines tumor necrosis factoralpha TNFα interleukins IL3 IL6 IL11103 The cytokines important regulators inflammation cell growth maturation key roles thrombopoiesis elevated cirrhotic patients proportion degree liver disease104 In patients alcoholic cirrhosis endotoxin levels significantly higher thrombocytopenia thrombocytopenia platelet counts inversely correlated endotoxin levels105 Endotoxin stimulates Bcell activity production IgG including PAIgG increases removal platelets circulation99 It contributes thrombo cytopenia triggering disseminated intravascular coagu lation DIC platelet activation aggregation platelet tolllike receptors106 Platelet consumption activation plateletmonoctye aggregates induced endotoxin107 endotoxemia impairs ADAMTS13 activity promotes thrombotic complications thrombocytopenia57 TNFα inflammatory cytokines suppress hepatic production TPO105 inhibit growth differen tiation megakaryocytes108 induce platelet apoptosis109 Finally TNFα induces vascular nitric oxide production110 main mediator development portal hypertension suppresses TPO production111 Cirrhosis predispose patients excessive response lipopolysaccharide LPS component cell walls Gramnegative bacteria directly increases platelet aggregation animal models In experimental animals human cells cirrhotic patients ex vivo LPS induces higher levels TNFα IL6 noncir rhotic controls112 Bacterial infection Thrombocytopenia commonly develops patients infection especially sepsis In retrospective review patients admitted Medical Intensive Care Unit severe sepsis septic shock thrombocytopenia developed 46 submit manuscript wwwdovepresscom Dovepress Hepatic Medicine Evidence Research 20168 Dovepress Thrombocytopenia chronic liver disease 476 patients113 Infection common patients cirrhosis general population The overall incidence infection patients liver disease estimated 47114 Multiple sources infection common advanced cirrhosis including spontaneous bacterial peritonitis urinary tract infection pneumonia Patients cirrhosis increased risk developing sepsis sepsisinduced organ failure sepsisrelated death115 Mechanisms sepsis lead thrombocytopenia include intensification adverse effects endotoxemia TNFα increased patients sepsis TNFα levels higher patients sepsis thrombocy topenia116 TNFα released infection trigger DIClike picture hyperfibrinolysis increased platelet activation adhesion endothelium117 TNFα triggers platelet activation amplifies platelet response collagen vitro118 Activation coagulation sepsis results fibrin clot formation consumption platelets119 Immune mechanisms implicated120 PF4 forms immune complexes heparin polyanions addition binding bacteria expos ing neoantigens inciting antibody formation Specif ically PF4 demonstrated bind negatively charged LPS Gramnegative bacteria121 This PF4LPS complex immunogenic elicit crossreacting antibodies PF4heparin complex resulting spontaneous HITlike picture Accordingly antiPF4heparin antibody titers higher patients bacteremia122 Finally endogenous heparinoids detected cirrhotic patients setting infection disappear following resolution Although associated impaired coagulation effect platelet count detected123 Conclusion Thrombocytopenia common CLD etiologies complicated multifactorial phenomenon Recent advances elucidating pathways platelet production consumption led significant improvements understanding thrombocytopenia CLD An indepth understanding pathophysiology thrombocytopenia CLD crucial considering treatment strategies Acknowledgment The authors grateful Nadia Nieves assistance development figures Disclosure Samuel Sigal received research support GSK Oscar Mitchell David Feldman Marla Diakow report conflicts work References 1 Qamar AA Grace ND Groszmann RJ et al Incidence prevalence clinical significance abnormal hematologic indices compensated cirrhosis Clin Gastroenterol Hepatol 200976689695 2 Bashour FN Teran JC Mullen KD Prevalence peripheral blood cytopenias hypersplenism patients nonalcoholic chronic liver disease Am J Gastroenterol 2000951029362939 3 Sheikh MY Raoufi R Atla PR et al Prevalence cirrhosis patients thrombocytopenia receive bone marrow biopsy Saudi J Gastroenterol 2012184257262 4 Poynard T Bedossa P Age platelet count simple index pre dicting presence histological lesions patients antibodies hepatitis C virus METAVIR CLINIVIR Cooperative Study Groups J Viral Hepat 199743199208 5 Hayashi H Beppu T Shirabe K et al Management thrombocytopenia liver cirrhosis review World J Gastroenterol 20142010 25952605 6 Aster RH Pooling platelets spleen role pathogen esis hypersplenic thrombocytopenia J Clin Invest 1966455 645657 7 Wendling F Tambourin P The oncogene VMPL putative truncated cytokine receptor immortalizes hematopoietic progenitors Nouv Rev Fr Hematol 1991332145146 8 Vigon I Mornon JP Cocault L et al Molecular cloning char acterization MPL human homolog vmpl oncogene identification member hematopoietic growth factor receptor superfamily Proc Natl Acad Sci U S A 1992891256405644 9 Methia N Louache F Vainchenker W et al Oligodeoxynucleotides antisense protooncogene cmpl specifically inhibit vitro megakaryocytopoiesis Blood 199382513951401 10 Lok S Kaushansky K Holly RD et al Cloning expression murine thrombopoietin cDNA stimulation platelet production vivo Nature 19943696481565568 11 Sauvage FJ Hass PE Spencer SD et al Stimulation mega karyocytopoiesis thrombopoiesis cMpl ligand Nature 19943696481533538 12 Stoffel R Wiestner A Skoda RC Thrombopoietin thrombocytopenic mice evidence regulation mRNA level direct regulatory role platelets Blood 1996872567573 13 Fielder PJ Gurney AL Stefanich E et al Regulation thrombopoi etin levels cmplmediated binding platelets Blood 1996876 21542161 14 Saur SJ Sangkhae V Geddis AE et al Ubiquitination degra dation thrombopoietin receptor cMpl Blood 20101156 12541263 15 Sattler M Durstin MA Frank DA et al The thrombopoietin receptor cMPL activates JAK2 TYK2 tyrosine kinases Exp Hematol 199523910401048 16 Rouyez MC Boucheron C Gisselbrecht S et al Control thrombopoi etininduced megakaryocytic differentiation mitogenactivated protein kinase pathway Mol Cell Biol 199717949915000 17 Gurney AL CarverMoore K Sauvage FJ et al Thrombocytopenia cmpldeficient mice Science 1994265517714451447 18 Kawasaki T Takeshita A Souda K et al Serum thrombopoietin levels patients chronic hepatitis liver cirrhosis Am J Gastroenterol 199994719181922 19 Giannini E Botta F Borro P et al Relationship thrombopoietin serum levels liver function patients chronic liver disease related hepatitis C virus infection Am J Gastroenterol 20039811 25162520 Hepatic Medicine Evidence Research 20168 submit manuscript wwwdovepresscom Dovepress 47 Mitchell et al Dovepress 20 PeckRadosavljevic M Zacherl J Meng YG et al Is inadequate throm bopoietin production major cause thrombocytopenia cirrhosis liver J Hepatol 1997271127131 21 Martin TG 3rd Somberg KA Meng YG et al Thrombopoietin levels patients cirrhosis orthotopic liver transplantation Ann Intern Med 19971274285288 22 Koike Y Yoneyama A Shirai J et al Evaluation thrombopoiesis thrombocytopenic disorders simultaneous measurement reticu lated platelets blood serum thrombopoietin concentrations Thromb Haemost 199879611061110 23 Zeldis JB Mugishima H Steinberg HN et al In vitro hepatitis B virus infection human bone marrow cells J Clin Invest 1986782 411417 24 Wang CS Yao WJ Wang ST et al Strong association hepatitis C virus HCV infection thrombocytopenia implications survey community hyperendemic HCV infection Clin Infect Dis 2004396790796 25 Bordin G Ballare M Zigrossi P et al A laboratory thrombokinetic study HCVassociated thrombocytopenia direct role HCV bone marrow exhaustion Clin Exp Rheumatol 199513Suppl 13 S39S43 26 GarciaSuarez J Burgaleta C Hernanz N et al HCVassociated thrombocytopenia clinical characteristics platelet response recombinant alpha2binterferon therapy Br J Haematol 20001101 98103 41 Allen DW Manning N Abnormal phospholipid metabolism spur cell anemia decreased fatty acid incorporation phosphatidyletha nolamine increased incorporation acylcarnitine spur cell anemia erythrocytes Blood 199484412831287 42 Pascoe A Kerlin P Steadman C et al Spur cell anaemia hepatic iron stores patients alcoholic liver disease undergoing orthotopic liver transplantation Gut 1999452301305 43 Connell WR Kamm MA Ritchie JK et al Bone marrow toxicity caused azathioprine inflammatory bowel disease 27 years experience Gut 199334810811085 44 Dutta TK Badhe BA Ciprofloxacininduced bone marrow depression Postgrad Med J 199975887571573 45 Yamane A Nakamura T Suzuki H et al Interferonalpha 2binduced thrombocytopenia caused inhibition platelet production proliferation endomitosis human megakaryocytes Blood 20081123542550 46 Sata M Yano Y Yoshiyama Y et al Mechanisms thrombocytopenia induced interferon therapy chronic hepatitis B J Gastroenterol 1997322206210 47 PeckRadosavljevic M Wichlas M Pidlich J et al Blunted thrombopoietin response interferon alfainduced thrombocy topenia treatment hepatitis C Hepatology 1998285 14241429 48 Jandl JH Aster RH Increased splenic pooling pathogenesis hypersplenism Am J Med Sci 19672534383398 27 Lindenbaum J Lieber CS Hematologic effects alcohol man absence nutritional deficiency N Engl J Med 19692817 333338 49 Morris PW Patton TB Balint JA et al Portal hypertension conges tive splenomegaly portacaval shunt Gastroenterology 196242 555559 28 Cowan DH Hines JD Thrombocytopenia severe alcoholism Ann Intern Med 19717413743 29 Gross S Keefer V Newman AJ The platelets irondeficiency anemia I The response oral parenteral iron Pediatrics 196434 315323 30 Evstatiev R Bukaty A Jimenez K et al Iron deficiency alters megakaryopoiesis platelet phenotype independent thrombopoietin Am J Hematol 2014895524529 31 Choi SI Simone JV Platelet production experimental iron deficiency anemia Blood 1973422219228 32 Klerk G Rosengarten PC Vet RJ et al Serum erythropoietin EST titers anemia Blood 198158611641170 33 Loo M Beguin Y The effect recombinant human erythropoietin platelet counts strongly modulated adequacy iron supply Blood 1999931032863293 34 Park CH Valore EV Waring AJ et al Hepcidin urinary antimi crobial peptide synthesized liver J Biol Chem 200127611 78067810 50 Rios R Sangro B Herrero I et al The role thrombopoietin thrombocytopenia patients liver cirrhosis Am J Gastroenterol 2005100613111316 51 Siedlecki CA Lestini BJ KottkeMarchant KK et al Sheardependent changes threedimensional structure human von Willebrand factor Blood 199688829392950 52 Arya M Anvari B Romo GM et al Ultralarge multimers von Willebrand factor form spontaneous highstrength bonds platelet glycoprotein IbIX complex studies optical tweezers Blood 2002991139713977 53 Lian EC Pathogenesis thrombotic thrombocytopenic purpura ADAMTS13 deficiency Semin Thromb Hemost 2005 316625632 54 Tsai HM Physiologic cleavage von Willebrand factor plasma protease dependent conformation requires calcium ion Blood 1996871042354244 55 Ruggeri ZM Mechanisms shearinduced platelet adhesion aggregation Thromb Haemost 1993701119123 35 Nemeth E Tuttle MS Powelson J et al Hepcidin regulates cellular iron efflux binding ferroportin inducing internalization Science 2004306570420902093 56 Uemura M Fujimura Y Matsumoto M et al Comprehensive analysis ADAMTS13 patients liver cirrhosis Thromb Haemost 200899610191029 36 Pigeon C Ilyin G Courselaud B et al A new mouse liverspecific gene encoding protein homologous human antimicrobial peptide hepci din overexpressed iron overload J Biol Chem 200127611 78117819 37 Geddis AE Kaushansky K Crossreactivity erythropoietin thrombopoietin level Mpl account thrombo cytosis seen iron deficiency J Pediatr Hematol Oncol 20032511 919920 author reply 920 38 Roetto A Papanikolaou G Politou M et al Mutant antimicrobial peptide hepcidin associated severe juvenile hemochromatosis Nat Genet 20033312122 39 Deugnier Y Turlin B le Quilleuc D et al A reappraisal hepatic siderosis patients endstage cirrhosis practical implications diagnosis hemochromatosis Am J Surg Pathol 1997216 669675 40 Jaroszewicz J Rogalska M Flisiak R Serum prohepcidin reflects degree liver function impairment liver cirrhosis Biomarkers 2008135478485 57 Uemura M Fujimura Y Ko S et al Pivotal role ADAMTS13 func tion liver diseases Int J Hematol 20109112029 58 Oda A Miyakawa Y Druker BJ et al Thrombopoietin primes human platelet aggregation induced shear stress multiple agonists Blood 1996871146644670 59 Pereira J Accatino L Alfaro J et al Platelet autoantibodies patients chronic liver disease Am J Hematol 1995503173178 60 Sanjo A Satoi J Ohnishi A et al Role elevated plateletassociated immunoglobulin G hypersplenism thrombocytopenia chronic liver diseases J Gastroenterol Hepatol 2003186638644 61 Aoki Y Hirai K Tanikawa K Mechanism thrombocytopenia liver cirrhosis kinetics indium111 tropolone labelled platelets Eur J Nucl Med 1993202123129 62 Macchi L ClofentSanchez G Marit G et al PAICA method characterizing plateletassociated antibodies application study idiopathic thrombocytopenic purpura detection plateletbound c7E3 Thromb Haemost 1996766 10201029 48 submit manuscript wwwdovepresscom Dovepress Hepatic Medicine Evidence Research 20168 Dovepress Thrombocytopenia chronic liver disease 63 van Leeuwen EF van der Ven JT Engelfriet CP et al Specificity autoantibodies autoimmune thrombocytopenia Blood 1982591 2326 87 Collen D Identification properties new fastreacting plasmin inhibitor human plasma Eur J Biochem 1976691 209216 64 Cines DB Blanchette VS Immune thrombocytopenic purpura N Engl J Med 2002346139951008 65 George JN Woolf SH Raskob GE et al Idiopathic thrombocytopenic purpura practice guideline developed explicit methods American Society Hematology Blood 1996881340 88 Bajzar L Thrombin activatable fibrinolysis inhibitor antifibrinolytic pathway Arterioscler Thromb Vasc Biol 2000201225112518 89 Leiper K Croll A Booth NA et al Tissue plasminogen activator plasminogen activator inhibitors activatorinhibitor complex liver disease J Clin Pathol 1994473214217 66 Bassendine MF Collins JD Stephenson J et al Platelet associated immunoglobulins primary biliary cirrhosis cause thrombocy topenia Gut 1985261010741079 90 Van Thiel DH George M Fareed J Low levels thrombin activat able fibrinolysis inhibitor TAFI patients chronic liver disease Thromb Haemost 2001854667670 67 Arakawa Y Amaki S Miyakawa H et al PBCAIH overlap syndrome concomitant ITP Hashimotos disease positivity anti centromere antibody J Gastroenterol 2004395490495 68 Pawlotsky JM Bouvier M Fromont P et al Hepatitis C virus infection autoimmune thrombocytopenic purpura J Hepatol 1995236 635639 69 Chiao EY Engels EA Kramer JR et al Risk immune thrombocy topenic purpura autoimmune hemolytic anemia 120 908 US veterans hepatitis C virus infection Arch Intern Med 20091694 357363 70 Misiani R Bellavita P Fenili D et al Hepatitis C virus infection patients essential mixed cryoglobulinemia Ann Intern Med 19921177573577 71 Steeper TA Horwitz CA Moore SB et al Severe thrombocytope nia EpsteinBarr virusinduced mononucleosis West J Med 19891502170173 91 Kujovich JL Hemostatic defects end stage liver disease Crit Care Clin 2005213563587 92 Stein SF Harker LA Kinetic functional studies platelets fibrinogen plasminogen patients hepatic cirrhosis J Lab Clin Med 1982992217230 93 Ikura Y Ohsawa M Okada M et al The significance platelet consumption development thrombocytopenia patients cirrhosis Am J Med Sci 20133463199203 94 Boylan JF Klinck JR Sandler AN et al Tranexamic acid reduces blood loss transfusion requirements coagulation factor use primary orthotopic liver transplantation Anesthesiology 1996855 10431048 discussion 1030A1031A 95 Porte RJ Molenaar IQ Begliomini B et al Aprotinin transfu sion requirements orthotopic liver transplantation multicentre randomised doubleblind study EMSALT Study Group Lancet 2000 355921213031309 72 Weksler BB Review article pathophysiology thrombocytopenia hepatitis C virus infection chronic liver disease Aliment Phar macol Ther 200726Suppl 11319 96 Dalmau A Sabate A Koo M et al The prophylactic use tranexamic acid aprotinin orthotopic liver transplantation comparative study Liver Transpl 2004102279284 73 Mayo MJ Extrahepatic manifestations hepatitis C infection Am J Med Sci 20033253135148 74 Nagamine T Ohtuka T Takehara K et al Thrombocytopenia associated hepatitis C viral infection J Hepatol 1996242135140 75 Hamaia S Li C Allain JP The dynamics hepatitis C virus bind ing platelets 2 mononuclear cell lines Blood 2001988 22932300 76 Panzer S Seel E Is increased frequency autoimmune throm bocytopenia hepatitis C infection A review Wien Med Wochenschr 20031531920417420 97 Gunawan B Runyon B The efficacy safety epsilon aminocaproic acid treatment patients cirrhosis hyperfibrinolysis Aliment Pharmacol Ther 2006231115120 98 Lumsden AB Henderson JM Kutner MH Endotoxin levels measured chromogenic assay portal hepatic peripheral venous blood patients cirrhosis Hepatology 198882232236 99 Kalambokis G Tsianos EV Endotoxaemia pathogenesis cytopenias liver cirrhosis Could oral antibiotics raise blood counts Med Hypotheses 2011761105109 100 Wiest R GarciaTsao G Bacterial translocation BT cirrhosis 77 Visentin GP Liu CY Druginduced thrombocytopenia Hematol Oncol Hepatology 2005413422433 Clin North Am 2007214685696 vi 78 George JN Raskob GE Shah SR et al Druginduced thrombocytope nia systematic review published case reports Ann Intern Med 199812911886890 79 Dourakis SP Deutsch M Hadziyannis SJ Immune thrombocytopenia alphainterferon therapy J Hepatol 1996256972975 80 Arena R Cecinato P Lisotti A et al Severe immune thrombocytopenia peginterferonalpha2a ribavirin telaprevir treatment comple tion case report systematic review literature World J Hepatol 201571217181722 81 Alberio L Kimmerle S Baumann A et al Rapid determination antiheparinplatelet factor 4 antibody titers diagnosis heparin induced thrombocytopenia Am J Med 20031147528536 82 Newman PM Chong BH Heparininduced thrombocytopenia new evidence dynamic binding purified antiPF4heparin antibodies platelets resultant platelet activation Blood 2000961182187 83 Aster RH Bougie DW Druginduced immune thrombocytopenia N Engl J Med 20073576580587 84 Warkentin TE Druginduced immunemediated thrombocytopenia purpura thrombosis N Engl J Med 20073569891893 85 Wiman B Collen D Molecular mechanism physiological fibrinolysis Nature 19782725653549550 86 Hersch SL Kunelis T Francis RB Jr The pathogenesis accelerated fibrinolysis liver cirrhosis critical role tissue plasminogen activator inhibitor Blood 198769513151319 101 Kuratsune H Koda T Kurahori T The relationship endo toxin phagocytic activity reticuloendothelial Hepatogastroenterology 19833037982 102 GarciaTsao G Wiest R Gut microflora pathogenesis complications cirrhosis Best Pract Res Clin Gastroenterol 2004 182353372 103 Deviere J Content J Denys C et al Excessive vitro bacterial lipopolysaccharideinduced production monokines cirrhosis Hepatology 1990114628634 104 Lin RS Lee FY Lee SD et al Endotoxemia patients chronic liver diseases relationship severity liver diseases presence esophageal varices hyperdynamic circulation J Hepatol 1995 222165172 105 Kalambokis GN Mouzaki A Rodi M et al Rifaximin improves thrombocytopenia patients alcoholic cirrhosis association reduction endotoxaemia Liver Int 2012323467475 106 Itoh H Cicala C Douglas GJ et al Platelet accumulation induced bacterial endotoxin rats Thromb Res 1996836405419 107 Panasiuk A Zak J Kasprzycka E et al Blood platelet mono cyte activations relation stages liver cirrhosis World J Gastroenterol 2005111827542758 108 Jelkmann W Wolff M Fandrey J Modulation production erythropoietin cytokines vitro studies clinical implications Contrib Nephrol 1990876877 109 Li J Xia Y Bertino AM et al The mechanism apoptosis human platelets storage Transfusion 2000401113201329 Hepatic Medicine Evidence Research 20168 submit manuscript wwwdovepresscom Dovepress 49 Mitchell et al Dovepress 110 Nathan C Nitric oxide secretory product mammalian cells FASEB J 199261230513064 111 Schobersberger W Hoffmann G Fandrey J Nitric oxide donors sup press erythropoietin production vitro Pflugers Arch 19964326 980985 112 Gustot T Durand F Lebrec D et al Severe sepsis cirrhosis Hepatology 200950620222033 113 Venkata C Kashyap R Farmer JC et al Thrombocytopenia adult patients sepsis incidence risk factors association clinical outcome J Intensive Care 2013119 114 Caly WR Strauss E A prospective study bacterial infections patients cirrhosis J Hepatol 1993183353358 115 Foreman MG Mannino DM Moss M Cirrhosis risk factor sepsis death analysis National Hospital Discharge Survey Chest 2003124310161020 116 Wang YQ Wang B Liang Y et al Role platelet TLR4 expres sion pathogensis septic thrombocytopenia World J Emerg Med 2011211317 117 Gawaz M Dickfeld T Bogner C et al Platelet function septic mul tiple organ dysfunction syndrome Intensive Care Med 1997234 379385 118 Pignatelli P De Biase L Lenti L et al Tumor necrosis factoralpha trigger platelet activation patients heart failure Blood 2005106619921994 119 Warkentin TE Aird WC Rand JH Plateletendothelial interactions sepsis HIT antiphospholipid syndrome Hematology Am Soc Hematol Educ Program 2003497519 120 Kalambokis G Tsianos EV Thrombocytopenia associated chronic liver disease effects rifaximin platelet count Am J Gastroenterol 20101051227052707 121 Krauel K Hackbarth C Furll B et al Heparininduced thrombocy topenia vitro studies interaction dabigatran rivaroxaban lowsulfated heparin platelet factor 4 antiPF4heparin antibodies Blood 2012119512481255 122 Pongas G Dasgupta SK Thiagarajan P Antiplatelet factor 4heparin antibodies patients gram negative bacteremia Thromb Res 20131322217220 123 Montalto P Vlachogiannakos J Cox DJ et al Bacterial infection cirrhosis impairs coagulation heparin effect prospective study J Hepatol 2002374463470 124 Spleen webpage Internet Redondo Beach CA Pacific Health Wellness 2014 Available httpphawscomspleen Accessed February 18 2016 125 Liver Cirrhosis webpage Internet Seattle WA Cognition Studio Available httpcognitionstudiocom Accessed March 23 2016 Hepatic Medicine Evidence Research Publish work journal Hepatic Medicine Evidence Research international peer reviewed open access journal covering aspects adult pedi atric hepatology clinic laboratory including following topics Pathology pathophysiology hepatic disease Investigation treatment hepatic disease Pharmacology drugs Dovepress treatment hepatic disease Issues patient safety quality care considered The manuscript management completely online includes quick fair peerreview easy use Visit httpwwwdovepresscom testimonialsphp read real quotes published authors Submit manuscript httpwwwdovepresscomhepaticmedicineevidenceandresearchjournal 50 submit manuscript wwwdovepresscom Dovepress Hepatic Medicine Evidence Research 20168